Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Hepatology. 2015 Mar 20;61(5):1591–1602. doi: 10.1002/hep.27665

Figure 1. Treatment with the SDF1α/CXCR4 inhibitor AMD3100 plus sorafenib inhibits primary tumor growth, incidence of lung metastasis formation and improves overall survival in orthotopic HCC models.

Figure 1

(A) While sorafenib (SOR) treatment alone marginally delays HCC growth, the addition of AMD3100 (AMD) to SOR – but not AMD alone – induces an additional significant delay in tumor growth (n=8; *p<0.05, **P<0.01). (B) The number of lung metastatic nodules is significantly reduced in AMD-treated mice. (C) Overall survival is significantly prolonged only in orthotopic HCC-bearing mice treated with SOR and AMD. Data are representative of at least two independent experiments and are presented as mean±SEM (n=10). *P<0.05; **P<0.01.